| 1 |
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial
Richard C. Dodel et al. · The Lancet Neurology
Open access |
30 Jan 2013 |
186 |
| 2 |
Mast cells, brain inflammation and autism
Theoharis Constantin Theoharides, Julia Marie Stewart, Smaro Panagiotidou et al. · European Journal of Pharmacology
|
3 May 2015 |
138 |
| 3 |
Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency
John B. Hagan, Mary Beth Fasano, Sheldon L. Spector et al. · Journal of Clinical Immunology
Open access |
7 May 2010 |
131 |
| 4 |
Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033
Jonathan Q. Tran, Jitesh Rana, Frederik Barkhof et al. · Neurology Neuroimmunology & Neuroinflammation
Open access |
Aug 2014 |
125 |
| 5 |
Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America
Daniel Suez, Mark R. Stein, Sudhir Gupta et al. · Journal of Clinical Immunology
Open access |
31 Aug 2016 |
65 |
| 6 |
Pharmacokinetics of Subcutaneous IgPro20 in Patients with Primary Immunodeficiency
Richard L. Wasserman, Isaac Melamed, Robert P. Nelson et al. · Clinical Pharmacokinetics
|
10 May 2011 |
65 |
| 7 |
Evaluation of the Cunningham Panel™ in pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS): Changes in antineuronal antibody titers parallel changes in patient symptoms
Craig D. Shimasaki, Richard E. Frye, Rosario Rich Trifiletti et al. · Journal of Neuroimmunology
Open access |
14 Dec 2019 |
60 |
| 8 |
Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency
Richard L. Wasserman, Isaac Melamed, Mark R. Stein et al. · Journal of Clinical Immunology
Open access |
25 May 2016 |
50 |
| 9 |
A pilot study of high‐dose intravenous immunoglobulin 5% for autism: Impact on autism spectrum and markers of neuroinflammation
Isaac Melamed, Melinda Heffron, Alessandro Testori et al. · Autism Research
|
10 Feb 2018 |
45 |
| 10 |
Recombinant Human Hyaluronidase Facilitated Subcutaneous Immunoglobulin Treatment in Pediatric Patients with Primary Immunodeficiencies: Long-Term Efficacy, Safety and Tolerability
Richard L. Wasserman, Isaac Melamed, Lisa J. Kobrynski et al. · Immunotherapy
Open access |
28 Jul 2016 |
40 |
| 11 |
Evaluation of Intravenous Immunoglobulin in Pediatric Acute-Onset Neuropsychiatric Syndrome
Isaac Melamed, Roger H. Kobayashi, Maeve O’Connor et al. · Journal of Child and Adolescent Psychopharmacology
Open access |
18 Feb 2021 |
31 |
| 12 |
Anti-LINGO-1 has no detectable immunomodulatory effects in preclinical and phase 1 studies
Ann M. Ranger, Soma S. Ray, Suzanne T. Szak et al. · Neurology Neuroimmunology & Neuroinflammation
Open access |
16 Dec 2017 |
31 |
| 13 |
Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease
Richard L. Wasserman, William R. Lumry, James B. Harris et al. · Journal of Clinical Immunology
Open access |
20 Jun 2016 |
30 |
| 14 |
Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies
Roger H. Kobayashi, Sudhir Gupta, Isaac Melamed et al. · Frontiers in Immunology
Open access |
4 Feb 2019 |
22 |
| 15 |
Pharmacokinetics of a novel human intravenous immunoglobulin 10% in patients with primary immunodeficiency diseases: Analysis of a phase III, multicentre, prospective, open-label study
Isaac Melamed, Michael Borte, Laurenz Trawnicek et al. · European Journal of Pharmaceutical Sciences
Open access |
6 Mar 2018 |
20 |
| 16 |
Attention Deficit Disorder and Allergic Rhinitis: Are They Related?
Isaac Reuven Melamed, Melinda Heffron · Journal of Immunology Research
Open access |
2016 |
20 |
| 17 |
Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga®) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study
Michael Borte, Isaac Melamed, Grażyna Pulka et al. · Journal of Clinical Immunology
Open access |
28 Jul 2017 |
16 |
| 18 |
Subcutaneous Immunoglobulins: Product Characteristics and Their Role in Primary Immunodeficiency Disease
Isaac Melamed, Alessandro Testori, Zvi Spirer · International Reviews of Immunology
|
7 Dec 2012 |
16 |
| 19 |
Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex® 10% Versus Gammaplex® 5% in Subjects with Primary Immunodeficiency
Richard L. Wasserman, Isaac Melamed, Mark R. Stein et al. · Journal of Clinical Immunology
Open access |
18 Mar 2017 |
15 |
| 20 |
Efficacy and safety of Gammaplex® 5% in children and adolescents with primary immunodeficiency diseases
Isaac Melamed, Sudhir Gupta, M Stratford Bobbitt et al. · Clinical & Experimental Immunology
Open access |
23 Dec 2015 |
14 |
| 21 |
IVIG response in pediatric acute-onset neuropsychiatric syndrome correlates with reduction in pro-inflammatory monocytes and neuropsychiatric measures
Isaac Melamed, Shamma Shakila Rahman, Heather Pein et al. · Frontiers in Immunology
Open access |
3 Oct 2024 |
13 |
| 22 |
Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens
Sudhir Gupta, James DeAngelo, Isaac Melamed et al. · Journal of Clinical Immunology
Open access |
9 May 2023 |
11 |
| 23 |
Angiographic Evaluation of Cranial Venous Outflow Patterns in Patients With and Without Idiopathic Intracranial Hypertension
Mithun G. Sattur, Matthew Robert Amans, Kyle Michael Fargen et al. · Operative Neurosurgery
|
26 Sep 2022 |
11 |
| 24 |
Intravenous Immunoglobulin 10% in Children with Primary Immunodeficiency Diseases
Hans D. Ochs, Isaac Melamed, Michael Borte et al. · Immunotherapy
Open access |
8 Aug 2018 |
11 |
| 25 |
On the Use of Ratio Statistics for the Evaluation of Operational Cloud Seeding Programs
Bernard A. Silverman · The Journal of Weather Modification
Open access |
Apr 2007 |
11 |
| 26 |
Long-term efficacy, safety, and tolerability of a subcutaneous immunoglobulin 16.5% (cutaquig®) in the treatment of patients with primary immunodeficiencies
Roger H. Kobayashi, Jiří Litzman, Isaac Melamed et al. · Clinical & Experimental Immunology
Open access |
8 Oct 2022 |
10 |
| 27 |
Canadian Society of Allergy and Clinical Immunology annual scientific meeting 2016
and the Canadian Healthy Infant Longitudinal Development Study Investigators et al. · Allergy Asthma and Clinical Immunology
Open access228 authors |
7 Apr 2017 |
8 |
| 28 |
Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease
Jennifer R. Heimall, Junliang Chen, Joseph A. Church et al. · Journal of Clinical Immunology
|
24 Jun 2016 |
7 |
| 29 |
Long-Term Safety and Effectiveness of Sebetralstat: Interim Analysis of KONFIDENT-S Open-label Extension
Henriette Farkas et al. · The Journal of Allergy and Clinical Immunology In Practice
Open access |
29 Aug 2025 |
6 |
| 30 |
Neurologic manifestations of hereditary angioedema
Alessandro Testori, Isaac Melamed · Annals of Allergy Asthma & Immunology
|
19 Dec 2016 |
6 |
| 31 |
Long-Term Tolerability and Safety Of Facilitated-Subcutaneous Infusion Of Human Immune Globulin G (IgG), 10%, and Recombinant Human Hyaluronidase (rHuPH20) (IGHy): A Phase 3 Extension Study In Patients With Primary Immunodeficiencies (PIs)
Isaac Reuven Melamed, Richard L. Wasserman, Mark R. Stein et al. · Journal of Allergy and Clinical Immunology
|
23 Jan 2014 |
6 |
| 32 |
Treatment of Children with Primary Immunodeficiencies with a Subcutaneous Immunoglobulin 16.5% (Cutaquig ® [Octanorm])
Roger H. Kobayashi, J. Fernando Mandujano, Syed M. Rehman et al. · Immunotherapy
Open access |
6 May 2021 |
5 |
| 33 |
A new subset of common variable immune deficiency characterized by reduced C1 esterase inhibitor levels
Isaac Melamed, Melinda Heffron, Sean P. McGee et al. · Annals of Allergy Asthma & Immunology
|
26 Jun 2015 |
5 |
| 34 |
The Benefit of Montelukast in Atopic Dermatitis Induced by Food Allergies
Isaac Reuven Melamed, Lacey B. Robinson, Melinda Heffron · Journal of Allergy and Clinical Immunology
|
Feb 2010 |
4 |
| 35 |
An Analysis of Safety and Tolerability Data on 10%, 16%, and 20% Formulations of Subcutaneous Immunoglobulin (IGSC)
Isaac Reuven Melamed, A. C. McDonald, ANN G. NEFF et al. · Journal of Allergy and Clinical Immunology
|
Feb 2011 |
4 |
| 36 |
BT595, a 10% Human Normal Immunoglobulin, for Replacement Therapy of Primary Immunodeficiency Disease: Results of a Subcohort Analysis in Children
Gergely Kriván, Michael Borte, Pere Soler‐Palacín et al. · Journal of Clinical Immunology
Open access |
16 Nov 2022 |
3 |
| 37 |
Recombinant Human C1 Esterase Inhibitor for the Management of Adverse Events Related to Intravenous Immunoglobulin Infusion in Patients With Common Variable Immunodeficiency or Polyneuropathy: A Pilot Open-Label Study
Isaac Melamed, Holly Miranda, Melinda Heffron et al. · Frontiers in Immunology
Open access |
2 Mar 2021 |
3 |
| 38 |
Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients with Primary Immunodeficiency
J.J. Hagan, M.B. Fasano, Sheldon L. Spector et al. · Journal of Allergy and Clinical Immunology
|
Feb 2010 |
3 |
| 39 |
Tolerability and Efficacy of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (IGHy) in a Subset of Study Patients With Primary Immunodeficiency Disease (PIDD)
Richard L. Wasserman, Isaac Reuven Melamed, Mark R. Stein et al. · Journal of Allergy and Clinical Immunology
|
Feb 2012 |
3 |
| 40 |
Sebetralstat for On‐Demand Treatment of Mucosal Hereditary Angioedema Attacks in KONFIDENT‐S
Jonathan A. Bernstein et al. · Clinical and Translational Allergy
Open access |
Nov 2025 |
2 |
| 41 |
Does C1 esterase inhibitor play a role in post COVID-19 neurological symptoms? A randomized, double-blind, placebo-controlled, crossover, proof-of-concept study
Isaac Melamed, Caley Buckley, Mary Ellen Bayko et al. · Frontiers in Neurology
Open access |
6 Nov 2025 |
2 |
| 42 |
The “Perfect Cytokine Storm” of COVID-19
Alessandro Testori · Mayo Clinic Proceedings
Open access |
29 May 2020 |
2 |
| 43 |
Safety and Pharmacokinetics of Facilitated-Subcutaneous Infusion of Immune Globulin (Human), 10% and Recombinant Human Hyaluronidase (IGHy) in a Phase III Extension Study in Patients With Primary Immunodeficiency Disease (PIDD)
Isaac Reuven Melamed, Richard L. Wasserman, Mark R. Stein et al. · Journal of Allergy and Clinical Immunology
|
Feb 2012 |
2 |
| 44 |
Long-Term Efficacy and Safety of Recombinant Human Hyaluronidase (rHuPH20)- Facilitated Subcutaneous Infusion of Immunoglobulin G (IgG) (HyQvia; IGHy) in Patients with Primary Immunodeficiencies (PI)
Richard L. Wasserman, Mark R. Stein, Isaac Melamed et al. · Journal of Allergy and Clinical Immunology
|
Feb 2015 |
2 |
| 45 |
Building Your Practice with Fillers
Ron D. Shippert · The American Journal of Cosmetic Surgery
|
Jun 2007 |
1 |
| 46 |
Local Adverse Reaction Rates Decreased over Time during Treatment with Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Immunoglobulin G (IGHy) in Patients with Primary Immunodeficiency Disorders in the IGHy Phase 3 Studies
Mark R. Stein, Richard L. Wasserman, Isaac Reuven Melamed et al. · Journal of Allergy and Clinical Immunology
|
Feb 2016 |
1 |
| 47 |
Pharmacokinetics of RI-002, an Investigational Igiv Preparation
James J. Mond, Charlotte Cunningham‐Rundles, Ann Regina Falsey et al. · Journal of Allergy and Clinical Immunology
Open access |
Feb 2015 |
1 |
| 48 |
Sa.46. Autism as a Neuro-Immune Disease-the Benefit Effect of IVIG
Isaac Melamed, Angela McDonald, Mónica González-Magaldi · Clinical Immunology
|
2006 |
1 |
| 49 |
Pharmacokinetic Analysis (PK) of Immune Globulin Subcutaneous (Human), 10% (IGSC) Administered Intravenously or Subcutaneously in Subjects with Primary Immunodeficiency Diseases (PIDD)
Heinz Leibl, Richard L. Wasserman, Isaac Melamed et al. · Journal of Allergy and Clinical Immunology
Open access |
Feb 2011 |
1 |
| 50 |
Pharmacokinetics (PK) of Human Immunoglobulin 10% (IgG) Administered Intravenously (IGIV), Subcutaneously (IGSC) or Facilitated Subcutaneously with Recombinant Human Hyaluronidase (IGHy) in a Subset of Patients with Primary Immunodeficiency Disease (PIDD)
Mark R. Stein, Richard L. Wasserman, Isaac Reuven Melamed et al. · Journal of Allergy and Clinical Immunology
Open access |
Feb 2012 |
1 |